AVEO Pharmaceuticals Inc (AVEO)

0.61
NASDAQ : Health Care
Prev Close 0.61
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.56 / 1.42
Avg Volume 202.10K
Exchange NASDAQ
Shares Outstanding 75.86M
Market Cap 47.04M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AVEO Oncology Reports Third Quarter 2016 Financial Results And Provides Business Update

AVEO Oncology Reports Third Quarter 2016 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2016.

AVEO To Present At The 15th Annual BIO Investor Forum

AVEO To Present At The 15th Annual BIO Investor Forum

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 15th Annual BIO Investor Forum on Wednesday, October 19, 2016 at 11:30 AM Pacific Time.

AVEO Oncology Announces Proposed Settlement And Settlement Hearing In 2014 Stockholder Litigation

AVEO Oncology Announces Proposed Settlement And Settlement Hearing In 2014 Stockholder Litigation

AVEO Oncology (NASDAQ:AVEO) today announced that a settlement hearing will be held on December 19, 2016 at 3:00 p.

AVEO To Present At The 18th Annual Rodman & Renshaw Global Investment Conference

AVEO To Present At The 18th Annual Rodman & Renshaw Global Investment Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 18 th Annual Rodman & Renshaw Global Investment Conference on Monday, September 12, 2016 at...

AVEO Initiates The Evaluation Of Tivozanib In Combination With Bristol-Myers Squibb's Opdivo® (nivolumab) In Advanced Renal Cell Carcinoma

AVEO Initiates The Evaluation Of Tivozanib In Combination With Bristol-Myers Squibb's Opdivo® (nivolumab) In Advanced Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) today announced the initiation of a clinical evaluation of AVEO's oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), tivozanib, in combination with...

AVEO Oncology Reports Second Quarter 2016 Financial Results And Provides Business Update

AVEO Oncology Reports Second Quarter 2016 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2016.

AVEO To Present At The 2016 JMP Securities Life Science Conference

AVEO To Present At The 2016 JMP Securities Life Science Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.

AVEO Announces Dosing Of First Patient In The Pivotal Phase 3 TIVO-3 Study Of Tivozanib In Renal Cell Carcinoma

AVEO Announces Dosing Of First Patient In The Pivotal Phase 3 TIVO-3 Study Of Tivozanib In Renal Cell Carcinoma

AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Company's pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects...

AVEO Announces Closing Of Private Placement And Amended Term Loan To Fund Pivotal TIVO-3 Trial And Combination PD-1 Trial Of Tivozanib In Renal Cell Cancer

AVEO Announces Closing Of Private Placement And Amended Term Loan To Fund Pivotal TIVO-3 Trial And Combination PD-1 Trial Of Tivozanib In Renal Cell Cancer

AVEO Oncology (NASDAQ:AVEO) today announced that it has closed its previously announced private placement of 17,642,482 units, consisting of one share of common stock and a warrant to purchase one share of common stock, at...

AVEO Announces $17 Million Private Placement

AVEO Announces $17 Million Private Placement

AVEO Oncology (NASDAQ:AVEO) today announced that it entered into a securities purchase agreement for a private placement with a select group of qualified institutional buyers, institutional accredited investors and...

AVEO Oncology Reports First Quarter 2016 Financial Results And Provides Business Update

AVEO Oncology Reports First Quarter 2016 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2016.

AVEO Announces Filing Of Provisional Patent Applications For AV-353, A Notch 3-Specific Inhibitor Antibody For PAH

AVEO Announces Filing Of Provisional Patent Applications For AV-353, A Notch 3-Specific Inhibitor Antibody For PAH

AVEO Oncology (NASDAQ:AVEO) today announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, the Company's potent...

AVEO And CANbridge Life Sciences Announce Exclusive Licensing Agreement For AV-203 Outside Of North America

AVEO And CANbridge Life Sciences Announce Exclusive Licensing Agreement For AV-203 Outside Of North America

AVEO Oncology (NASDAQ:AVEO) and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, today announced an exclusive collaboration and license agreement in...

AVEO Oncology Reports Full Year 2015 Financial Results And Provides Business Update

AVEO Oncology Reports Full Year 2015 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2015 and provided a business update.

AVEO To Present At The 28th Annual ROTH Conference

AVEO To Present At The 28th Annual ROTH Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 28th Annual ROTH Conference on Wednesday, March 16, 2016, at 9:00 a.

EUSA Pharma And AVEO Announce Submission Of Marketing Authorization Application For Tivozanib In Advanced Renal Cell Carcinoma

EUSA Pharma And AVEO Announce Submission Of Marketing Authorization Application For Tivozanib In Advanced Renal Cell Carcinoma

EUSA Pharma, a newly-established specialty pharmaceutical business, and AVEO Oncology (NASDAQ:AVEO) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for...

AVEO Announces Acceptance Of Registration Dossier For Tivozanib In RCC By The Ministry Of Health Of The Russian Federation

AVEO Announces Acceptance Of Registration Dossier For Tivozanib In RCC By The Ministry Of Health Of The Russian Federation

AVEO Oncology (NASDAQ:AVEO) today announced that a registration dossier seeking to obtain marketing authorization of tivozanib as a first line treatment of advanced renal cell carcinoma ("RCC") has been accepted by the...

AVEO To Present At The 18th Annual BIO CEO & Investor Conference

AVEO To Present At The 18th Annual BIO CEO & Investor Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 9:00 a.

AVEO To Present At Biotech Showcase 2016

AVEO To Present At Biotech Showcase 2016

AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at Biotech Showcase 2016 on Wednesday, January 13, 2016 at 4:00 PM (PT) at the Parc 55 Wyndham in San...

AVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing Agreement

AVEO Pharmaceuticals (AVEO) Stock Pops on European Licensing Agreement

AVEO Pharmaceuticals (AVEO) stock is surging in mid-morning trading on Monday after the company said it secured a licensing agreement for its renal cell carcinoma treatment in Europe.

AVEO And EUSA Pharma Announce Exclusive Licensing Agreement For Tivozanib In Europe

AVEO And EUSA Pharma Announce Exclusive Licensing Agreement For Tivozanib In Europe

AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma, a newly-established specialty pharmaceutical business with global reach, today announced an exclusive license agreement in which AVEO has granted EUSA Pharma European rights to...

AVEO Oncology Reports Third Quarter 2015 Financial Results And Provides Business Update

AVEO Oncology Reports Third Quarter 2015 Financial Results And Provides Business Update

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2015 and provided a business update.

AVEO Announces Chairman Tuan Ha-Ngoc Steps Down

AVEO Announces Chairman Tuan Ha-Ngoc Steps Down

AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc, after 13 years of service and leadership at AVEO, has stepped down as Chairman and a Director of the Company's board of directors, effective November 6, 2015,...

When Eyeing Small Biotechs, Partnerships Are Huge

Key collaboration deals with deeper-pocketed concerns can improve the odds of investment success.

AVEO Announces Exclusive Worldwide License Agreement For The Development And Commercialization Of AV-380 And Related Antibodies

AVEO Announces Exclusive Worldwide License Agreement For The Development And Commercialization Of AV-380 And Related Antibodies

AVEO Oncology (NASDAQ:AVEO) today announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO's first-in-class, potent, humanized inhibitory antibody targeting growth...

AVEO Oncology Reports Second Quarter 2015 Financial Results

AVEO Oncology Reports Second Quarter 2015 Financial Results

AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2015.

AVEO Oncology To Host Midyear Update Conference Call On August 10, 2015

AVEO Oncology To Host Midyear Update Conference Call On August 10, 2015

AVEO Oncology (NASDAQ:AVEO) today announced that management will host a conference call on Monday, August 10, 2015, at 10:00 a.

AVEO Oncology Announces Exclusive Licensing Agreement With Pharmstandard For Tivozanib In Russia, Ukraine And CIS

AVEO Oncology Announces Exclusive Licensing Agreement With Pharmstandard For Tivozanib In Russia, Ukraine And CIS

AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into an exclusive license agreement with a subsidiary of Pharmstandard Group, the largest Russian pharmaceutical group ("Pharmstandard"), for the development,...